2
Clinical Trials associated with JYP-0322A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of JYP0322 in Patients With Solid Tumors
An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced/metastatic solid tumors .
JYP0322 在ROS1 基因融合阳性局部晚期/转移性实体瘤患者中安全 性、耐受性、药代动力学特征及初步有效性的I 期临床研究
[Translation] A Phase I clinical study of the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of JYP0322 in patients with ROS1 gene fusion-positive locally advanced/metastatic solid tumors
确定JYP0322 片的最大耐受剂量(MTD),以及Ⅱ期推荐剂量(RP2D)。
[Translation] Determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of JYP0322 tablets.
100 Clinical Results associated with JYP-0322
100 Translational Medicine associated with JYP-0322
100 Patents (Medical) associated with JYP-0322
100 Deals associated with JYP-0322